Q2 FY2026 EarningsQ2 FY2026 significantly beat consensus across the top and bottom lines: revenue reached $101.9M vs. $96.0M expected, and GAAP EPS was $0.29 (diluted) vs. $0.24 (midpoint). Growth was driven by strong DefenCath® sales ($66.1M) and the integration of the Melinta portfolio ($35.8M). Notably, management raised FY 2026 Adjusted EBITDA guidance to $125M–$140M while maintaining revenue targets, reflecting enhanced operational efficiency despite post-TDAPA reimbursement headwinds.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Cormedix(CRMD) the Revenue is 101.93 M (+156.5%), Beat estimate;the EBIT is 42.91 M (+119.6%), Beat estimate;the EPS is 0.29 (+3.57%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.10B156.52%
0.10B141.71%
+0.01B14.81%
EBITExceed expectations
0.04B119.56%
0.03B77.13%
+0.01B42.43%
EPSExceed expectations
0.293.57%
0.23815.00%
+0.052018.57%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf